Current partner codePEPTIDESDE
NCT01924052·Not applicable·INTERVENTIONAL

CGRP Induced Migraine Attacks in Patients With High and Low Genetic Load

Status

Completed

Phase

Not applicable

Enrollment

40

Locations

0

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

The investigators hypothesized that migraine without patients with many genetic loci associated with migraine (high genetic load) would be more sensitive and get provoked more migraine attacks by calcitonin gene-related peptide (CGRP) compared to patients with few genetic loci associated with migraine (low genetic load).

Full detailed description

Migraine is a very prevalent neurological disorder with a strong genetic factor. The common forms of migraine have a multifactorial and polygenic pattern of inheritance and genetics research is crucial for a deeper understanding of migraine mechanisms. Recently, 12 genetic loci have been identified to be associated with migraine with (MA) and without aura (MA) in four large genome-wide association studies (GWAS). The functional consequences of these genetic loci in humans are yet unknown. Calcitonin gene-related peptide (CGRP) is a neuropeptide which plays a crucial role in the pathophysiology of migraine and is present in migraine relevant structures. CGRP can induce migraine attacks in MO patients via an adenosine monophosphate (cAMP) dependent pathway and CGRP antagonism is efficient in the treatment of migraine attacks. Also, a recent study has showed that intracellular accumulation of cAMP is crucial for the induction of migraine attacks. However, CGRP does not cause migraine attacks in familial hemiplegic migraine (FHM), an autosomal dominant subtype of MA. The phenotype of the migraine inducing effects of CGRP might therefore be linked to some of the 12 genetic susceptibility loci that have been identified. One of the genetic loci (rs13208321) is located in a gene (FHL5) that is associated with the regulation of cAMP-responsive elements.

Interventions

Treatment arms and agents.

DRUG

CGRP

Calcitonin-gene-related-peptide (CGRP)

Timeline

From registration to results.

  1. First posted

    Aug 16, 2013

  2. Study start

    Jun 2013

  3. Primary completion

    Aug 2013

  4. Study completion

    Aug 2013

  5. Results posted

    Not reported

  6. Registry updated

    Aug 2, 2022

Outcomes

What the study measures.

Primary outcomes

CGRP induced migraine attacks in patients with high and low genetic load

Time frame · Change from baseline in headache intensity at 12 hours after the start of infusion of CGRP

The difference in incidence of migraine-like attacks between patients with high genetic load and patients with low genetic load using verbal rating scale (VRS).

Secondary outcomes

CGRP induced migraine attacks in patients with high and low genetic load

Time frame · Change from baseline in headache intensity at 12 hours after the start of infusion of CGRP

The difference in area under the curve (AUC) for headache intensity scores (0-12 hours)

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
65 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: \- Migraine without aura patients genotyped for the 12 newly idetified gene variants associated with migraine. Exclusion Criteria: * Other primary headache * A history of cerebrovascular disease and other CNS- disease * A history suggesting ischaemic heart disease * Serious somatic and mental disease * Hypo- or hypertension * Abuse of alcohol or medicine (opioid analgesics). * Pregnant or breastfeeding women.

Study locations

0 registered sites.

No country data reported. Showing up to 24 locations stored in the fast local snapshot.

No study locations reported.

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Calcitonin.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.